Subcutaneous · GLP-1 agonist
GZR18
26 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
26
Active
18
Recruiting
6
Completed
7
Sites
38
Countries
3
Endpoints
217
Composite endpoints
1
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
11
Phase 1/2
2
Phase 2
4
Phase 3
9
Trials by status
Not yet recruiting
7
Recruiting
6
Active, not recruiting
5
Completed
7
Unknown
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
92
Weight & body composition
51
Other (unclassified)
33
Glycemic / diabetes
19
Cardiometabolic biomarkers
19
Patient-reported / QoL
3
Most-measured metrics
Top 20 metrics across this asset's endpoints
Body weight, % changeWeight
3
HbA1c, changeGlycemic
3
≥5% weight-loss respondersWeight
2
Body weight, absolute change (kg)Weight
2
Treatment-emergent AEs (any)Safety/PK
2
≥10% weight-loss respondersWeight
1
≥15% weight-loss respondersWeight
1
≥20% weight-loss respondersWeight
1
≥25% weight-loss respondersWeight
1
BMI, changeWeight
1
Waist circumference, changeWeight
1
Fasting glucose, changeGlycemic
1
Systolic BP, changeBiomarker
1
Diastolic BP, changeBiomarker
1
Total cholesterol, changeBiomarker
1
LDL-C, changeBiomarker
1
HDL-C, changeBiomarker
1
Triglycerides, changeBiomarker
1
HbA1c <7.0% achievementGlycemic
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
26 of 26